David Shaw’s enGene Therapeutics ENGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$341K Buy
+170,408
New +$315K ﹤0.01% 4431

Other funds holding ENGN

David Shaw's ENGN Position: Q3 2026 in Review

David Shaw opened a new position in enGene Therapeutics (ENGN) in Q3 2026: 170,408 shares worth $341K. The stake represents ﹤0.01% of the portfolio and ranks #4431 among its holdings.

60 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

  • David Shaw held 170,408 shares of enGene Therapeutics worth $341K as of Q3 2026.
  • enGene Therapeutics was a new David Shaw position in Q3 2026.
  • enGene Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q3 2026, its #4431 holding.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.